Announcement: SignalChem has changed its corporate name from “SignalChem Pharmaceutical Inc.” to “SignalChem Biotech Inc.” effective March 20th, 2019.

Phosphodiesterases

SignalChem offers a comprehensive range of active PDEs which are compatible with the susbstrates cAMP and cGMP. PDEs are important pharmacological targets for treating arterial hypertension, coronary heart disease, dementia, depression, asthma and schizophrenia.